- Home
- KTF vs IDYA Comparison
KTF vs IDYA Comparison
Compare KTF & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTF
- IDYA
- Stock Information
- Founded
- KTF 1988
- IDYA 2015
- Country
- KTF United States
- IDYA United States
- Employees
- KTF N/A
- IDYA N/A
- Industry
- KTF Finance Companies
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- KTF Finance
- IDYA Health Care
- Exchange
- KTF Nasdaq
- IDYA Nasdaq
- Market Cap
- KTF 384.3M
- IDYA 2.2B
- IPO Year
- KTF N/A
- IDYA 2019
- Fundamental
- Price
- KTF $9.47
- IDYA $26.23
- Analyst Decision
- KTF
- IDYA Strong Buy
- Analyst Count
- KTF 0
- IDYA 12
- Target Price
- KTF N/A
- IDYA $53.67
- AVG Volume (30 Days)
- KTF 103.3K
- IDYA 1.1M
- Earning Date
- KTF 01-01-0001
- IDYA 11-04-2024
- Dividend Yield
- KTF 3.54%
- IDYA N/A
- EPS Growth
- KTF N/A
- IDYA N/A
- EPS
- KTF 0.39
- IDYA N/A
- Revenue
- KTF N/A
- IDYA $3,922,000.00
- Revenue This Year
- KTF N/A
- IDYA N/A
- Revenue Next Year
- KTF N/A
- IDYA $251.89
- P/E Ratio
- KTF $23.10
- IDYA N/A
- Revenue Growth
- KTF N/A
- IDYA N/A
- 52 Week Low
- KTF $7.40
- IDYA $24.48
- 52 Week High
- KTF $9.12
- IDYA $47.74
- Technical
- Relative Strength Index (RSI)
- KTF 21.65
- IDYA 37.58
- Support Level
- KTF $9.95
- IDYA $24.48
- Resistance Level
- KTF $10.10
- IDYA $27.15
- Average True Range (ATR)
- KTF 0.09
- IDYA 1.34
- MACD
- KTF -0.06
- IDYA -0.11
- Stochastic Oscillator
- KTF 12.50
- IDYA 7.90
About KTF DWS Municipal Income Trust
DWS Municipal Income Trust is a closed-end, diversified investment management company. The investment objective is to provide high current income exempt from federal income tax by investing in a diversified portfolio of investment-grade tax-exempt securities. Its products include ETFs, Mutual Funds, Closed-End-Funds, Money Market Funds, and others.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.